JPRN-UMIN000002466已完成2 期
Multi-Center Phase II Clinical Trial on Efficacy and Safety of Interferon Alfa-n1 + Sorafenib Combination Therapy in Renal Cell Carcinoma - Phase II of Interferon Alfa-n1 + Sorafenib in Renal Cell Carcinoma
Japan RCC Trialist Collaborative Group (JRTCG)0 个研究点目标入组 45 人开始时间: 2009年9月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Congestive cardiac failure 2) Severe arrhythmias 3) Active or symptomatic angina pectoris or coronary artery disease 4) Poorly controlled hypertension 5) History of HIV infection, or active chronic hepatitis caused by type B or type C hepatitis virus 6) Active infection 7) Intracranial metastasis 8) Convulsive disorders requiring treatment with anticonvulsants 9) History of organ transplant 10) Poorly controlled depression 11) Autoimmune hepatitis 12) History of malignant tumors 13) Radiation therapy, except for palliative therapy, within 3 weeks prior to the start of treatment 14) Significantly invasive surgery within 4 weeks prior to the start of treatment 15) Use of G-CSF within 3 weeks prior to the start of treatment 16) Pts with a history of treatment using drugs targeting VEGF or VEGF receptor 17) Pts with a history of treatment using Raf kinase, MEK, farnesyl transferase inhibitors 18) Pts being treated with adrenocortical steroids 19) Pts being treated with Minor Bupleurum Formula 20) Pts who have or have had interstitial pulmonary disease 21) Pregnant or nursing patients 22) Pts who are unable to practice appropriate contraception throughout the study period 23) Pts who abuse drugs or who have health conditions, psychological states, or social circumstances which would interfere with participation in the study or assessment of results 24) Pts with diseases or disability potentially affecting drug assessment 25) Patients who have had, or are suspected of having, allergies to sorafenib, Interferon Alfa-n1, or other interferon formulations 26) Pts with a history of hypersensitivity to biological preparations such as vaccines 27) Patients for whom oral medication may be difficult to take 28) Patients who previously encountered difficulties in treatment with IFN alfa due to adverse events caused by IFN alfa, or patients in whom IFN alfa-induced adverse events persist to this day
研究者
相似试验
已完成
不适用
The efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary origin (CUP): prospective validation of diagnosis, classfication and metabolic responsesCarcinoma of unknown primary origin (CUP)CancerISRCTN17282276HS Greater Glasgow and Clyde (UK)59
进行中（未招募）
1 期
A clinical trial to evaluate the efficacy and safety ofpembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer. PANGEA-Breast”Patients with HER2-negative advanced breast cancer.MedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-001779-54-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)36
已完成
2 期
A multicenter phase II trial of the efficacy and safety of tadalafil with pre-eclampsia.pregnancy induced hypertensionJPRN-UMIN000024042Mie university hospital, Department of Obstetrics and Gynecology160
已完成
2 期
A multicenter phase II trial of the efficacy and safety of tadalafil in fetus with early-onset growth restriction.Fetal growth restrictionJPRN-UMIN000023778Mie university hospital, Department of Obstetrics and Gynecology140
招募中
不适用
A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase.Chronic Myeloid LeukemiaJPRN-UMIN000005843Epidemiological and Clinical Research Information Network (ECRIN)30